Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Jan;55(1):61–66. doi: 10.1038/bjc.1987.13

The clinical course of bone metastases from breast cancer.

R E Coleman, R D Rubens
PMCID: PMC2001575  PMID: 3814476

Abstract

All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics of the primary tumour were compared in patients relapsing first in bone or liver. Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade 1) tumours. The median survival was 24 months in those with disease apparently confined to the skeleton compared with 3 months after first relapse in liver. Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85% had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton developed hypercalcaemia. The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the UICC assessment criteria. The duration of survival in these patients was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coleman R. E., Rubens R. D. Bone metastases and breast cancer. Cancer Treat Rev. 1985 Dec;12(4):251–270. doi: 10.1016/0305-7372(85)90008-8. [DOI] [PubMed] [Google Scholar]
  3. Croton R., Cooke T., Holt S., George W. D., Nicolson R., Griffiths K. Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1289–1291. doi: 10.1136/bmj.283.6302.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lee Y. T. Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev. 1985;4(2):153–172. doi: 10.1007/BF00050693. [DOI] [PubMed] [Google Scholar]
  5. McNeil B. J. Value of bone scanning in neoplastic disease. Semin Nucl Med. 1984 Oct;14(4):277–286. doi: 10.1016/s0001-2998(84)80003-3. [DOI] [PubMed] [Google Scholar]
  6. Stewart J., King R., Hayward J., Rubens R. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat. 1982;2(3):243–250. doi: 10.1007/BF01806937. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES